

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus Pi/L4R lyophilisate and suspension for suspension for injection for dogs

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

#### Active substances:

#### Lyophilisate (live attenuated):

	Minimum	Maximum
Canine parainfluenza Type 2 virus, strain CPIV-2 Bio 15	10 <sup>3.1</sup> TCID <sub>50</sub> *	10 <sup>5.1</sup> TCID <sub>50</sub> *

#### Suspension (inactivated):

<i>Leptospira interrogans</i> serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089	ALR** titre ≥ 1:51
<i>Leptospira interrogans</i> serogroup Canicola serovar Canicola, strain MSLB 1090	ALR** titre ≥ 1:51
<i>Leptospira kirschneri</i> serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091	ALR** titre ≥ 1:40
<i>Leptospira interrogans</i> serogroup Australis serovar Bratislava, strain MSLB 1088	ALR** titre ≥ 1:51
Rabies virus, strain SAD Vnukovo-32	≥ 5 IU***

\* Tissue culture infectious dose 50%.

\*\* Antibody micro agglutination-lytic reaction.

\*\*\* International units.

#### Adjuvant:

Aluminium hydroxide	1.8 – 2.2 mg.
---------------------	---------------

For the full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Lyophilisate and suspension for suspension for injection.

The visual appearance is as follows:

Lyophilisate: spongy matter of white colour.

Suspension: pink colour with fine sediment.

### 4. CLINICAL PARTICULARS

#### 4.1 Target species

Dogs.

## 4.2 Indications for use, specifying the target species

Active immunisation of dogs from 8–9 weeks of age:

- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
- to prevent clinical signs, infection and urinary excretion caused by *L. interrogans* serogroup Australis serovar Bratislava,
- to prevent clinical signs and urinary excretion and reduce infection caused by *L. interrogans* serogroup Canicola serovar Canicola and *L. interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae,
- to prevent clinical signs and reduce infection and urinary excretion caused by *L. kirschneri* serogroup Grippotyphosa serovar Grippotyphosa and
- to prevent mortality, clinical signs and infection caused by rabies virus.

Onset of immunity:

- 2 weeks after a single vaccination from 12 weeks of age for rabies,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after completion of the primary course for *Leptospira* components.

Duration of immunity:

At least three years following the primary vaccination course for rabies. At least one year following the primary vaccination course for canine parainfluenza virus and *Leptospira* components. Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.

## 4.3 Contraindications

None.

## 4.4 Special warnings for each target species

A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Vaccinate healthy animals only.

## 4.5 Special precautions for use

### i) Special precautions for use in animals

Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.

The live attenuated virus vaccine strain CPiV may be shed by vaccinated dogs following vaccination. However, due to the low pathogenicity of the strain, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

iii) Other precautions

Not applicable.

#### 4.6 Adverse reactions (frequency and seriousness)

Dogs:

Common (1 to 10 animals / 100 animals treated):	injection site swelling <sup>1</sup>
Rare (1 to 10 animals / 10,000 animals treated):	hypersensitivity reaction <sup>2</sup> (anaphylaxis, angioedema, circulatory shock, collapse, diarrhoea, dyspnoea, vomiting) anorexia, decreased activity
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	hyperthermia, lethargy, malaise immune mediated haemolytic anaemia, immune mediated haemolytic thrombocytopenia, immune mediated polyarthritis

<sup>1</sup>A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.

<sup>2</sup>If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.

#### 4.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### **4.9 Amount(s) to be administered and administration route**

Subcutaneous use.

##### Dose and route of administration:

Aseptically reconstitute the lyophilisate with the suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Appearance of the reconstituted vaccine: pink/red, or yellowish colour with light opalescence.

##### Primary vaccination scheme:

Two doses of Versican Plus Pi/L4R 3–4 weeks apart from 8–9 weeks of age. The second dose should not be given before 12 weeks of age.

##### Rabies:

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. Therefore, the first dose may be given using Versican Plus Pi/L4. In this case the second vaccination with Versican Plus Pi/L4R should not be given before 12 weeks.

However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Some animals may also not show titres > 0.5 IU/ml after the primary vaccination. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside the UK, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of  $\geq 0.5$  IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres  $\geq 0.5$  IU/ml).

In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6-week old dogs.

##### Re-vaccination scheme:

A single dose of Versican Plus Pi/L4R should be given every 3 years. Annual re-vaccination is required for canine parainfluenza virus and *Leptospira* components. Therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

No adverse reactions other than those mentioned in section 4.6 were observed after administration of a 10-fold overdose of the vaccine. However, in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine.

#### 4.11 Withdrawal period(s)

Not applicable.

### 5. IMMUNOLOGICAL PROPERTIES

**Pharmacotherapeutic group:** Immunologicals for canidae, live and inactivated viral and inactivated bacterial vaccines.

**ATCvet Code:** QI07AJ.

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parainfluenza virus, *Leptospira interrogans* serogroup Australis serovar Bratislava, *Leptospira interrogans* serogroup Canicola serovar Canicola, *Leptospira kirschneri* serogroup Grippotyphosa serovar Grippotyphosa, *Leptospira interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and rabies virus.

### 6. PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Lyophilisate:

Trometamol  
Edetic Acid  
Sucrose  
Dextran 70

Suspension:

Sodium chloride  
Potassium chloride  
Potassium dihydrogen phosphate  
Disodium phosphate dodecahydrate  
Water for injections

#### 6.2 Major Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

#### 6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after reconstitution according to directions: use immediately.

#### 6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

## **6.5 Nature and composition of immediate packaging**

Type I glass vial containing 1 dose of lyophilisate closed with a bromobutyl rubber stopper and aluminium cap.

Type I glass vial containing 1 ml of suspension closed with a chlorobutyl rubber stopper and aluminium cap.

Pack sizes:

Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of suspension.

Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of suspension.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

## **8. MARKETING AUTHORISATION NUMBER**

Vm 42058/5087

## **9. DATE OF FIRST AUTHORISATION**

31 July 2014

## **10. DATE OF REVISION OF THE TEXT**

August 2023

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

## 11. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

A handwritten signature in black ink, appearing to read 'Dennett', written in a cursive style.

Approved: 10 August 2023